Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics

Dhawan, Dipali; Padh, Harish

doi:10.1016/j.diabres.2016.08.018

Cited by 16 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was shown that with respect to rs1225372 12% of the diabetic population with TT genotype were twice as unlikely to achieve a target HbA1c < 7% within 1 year of treatment initiation compared to 42% of the population with GG genotype [ 93 ]. These findings were replicated in some other studies in Indian and European populations [ 87 , 91 , 92 ]. In Asian population genetic variant rs290487 of TCF7L2 gene was found to influence the therapeutic efficacy.…”

Section: Genes Associated With Sulfonylurea/meglitinides Responsesupporting

confidence: 81%

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Nasykhova

Tonyan

Михайлова

et al. 2020

IJMS

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin resistance and progressively reduced insulin secretion, which leads to impaired glucose utilization, dyslipidemia and hyperinsulinemia and progressive pancreatic beta cell dysfunction. The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic. The well-known interindividual variability of T2D drug actions such as biguanides, sulfonylureas/meglitinides, DPP-4 inhibitors/GLP1R agonists and SGLT-2 inhibitors may be caused, among other things, by genetic factors. Pharmacogenetic findings may aid in identifying new drug targets and obtaining in-depth knowledge of the causes of disease and its physiological processes, thereby, providing an opportunity to elaborate an algorithm for tailor or precision treatment. The aim of this article is to summarize recent progress and discoveries for T2D pharmacogenetics and to discuss the factors which limit the furthering accumulation of genetic variability knowledge in patient response to therapy that will allow improvement the personalized treatment of T2D.

show abstract

Section: Genes Associated With Sulfonylurea/meglitinides Responsesupporting

confidence: 81%

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Nasykhova

Tonyan

Михайлова

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In contrast to the association of the rs7903146 SNP with lean body mass, the rs12255372 GT/TT genotype has been strongly associated with metabolic syndrome/ increased waist circumference. [23][24][25] Hence it could be suggested that the present study data may fall in line with these reports, as the rs12255372 positive participants tended to exhibit a relatively greater BMI and abnormal OGTT results.…”

Section: Discussionsupporting

confidence: 82%

Pilot studies on the prevalence and association of TCF7L2 polymorphisms in non-diabetic participants and type 2 diabetic patients of South Tamil Nadu

Ramanathan¹,

Murugan²,

Velayutham³

et al. 2019

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: Genetic predisposition plays a critical role in the incidence of type 2 diabetes mellitus (T2DM). While a few reports strongly associate TCF7L2 gene polymorphisms in the T2DM incidence in India, data pertaining to the prevalence of these polymorphisms in the south Tamil Nadu population has been lacking. Hence, the present study aims to determine the prevalence and association of the TCF7L2 gene variants rs7903146, rs12255372 in the regional population of south Tamil Nadu.Methods: Peripheral blood samples from controls, T2DM patients were utilized to isolate genomic DNA and genotyping was carried out using PCR based strategies, direct sequencing. Socio-demographic details, anthropometric measurements, determination of postprandial, random blood glucose levels and oral glucose tolerance test (OGTT) were further carried out to evaluate the predisposition risk for T2DM.Results: 50% of the control group participants and 73.9% of the T2DM patients were positive (CT/TT) for the TCF7L2 polymorphism rs7903146. The rs12255372 SNP was less prevalent in the controls, patients and was dispersed in only 25% of the controls and 60.9% (GT/TT) of the patients. The 60 minutes plasma glucose levels for the oral glucose tolerance test (OGTT) was higher (143.3±19.8) in the rs7903146 and rs12255372 positive control participants.Conclusions: The study results reveal that TCF7L2 polymorphisms are dispersed in the regional population and further large scale, long term follow up studies will aid preventive and therapeutic measures in T2DM.

show abstract

“…Moreover, T allele of the rs7903146 polymorphism has been supported in the German (OR = 1.57 [95% CI, 1.01‐2.45]) and Slovak ( P = .003) populations . This association is not observed in Indian patients treated with SU, although in this study the authors used a cut‐off point of 6.5% on A1C . Interestingly, Jovorsky et al reported that carriers of rs7903146 polymorphism T allele had a lower reduction in A1C in patients receiving gliclazide at 6 months of treatment, whereas in patients receiving sulphonylureas binding to K ATP channel AB sites (glimepiride, glibenclamide and glipizide), there was no difference.…”

Section: Resultsmentioning

confidence: 60%

CYP2C93* gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide

et al. 2018

View full text Add to dashboard Cite

show abstract

Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics

Cited by 16 publications

References 28 publications

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Pilot studies on the prevalence and association of TCF7L2 polymorphisms in non-diabetic participants and type 2 diabetic patients of South Tamil Nadu

CYP2C93* gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide

Contact Info

Product

Resources

About

Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics

Cited by 16 publications

References 28 publications

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Pilot studies on the prevalence and association of TCF7L2 polymorphisms in non-diabetic participants and type 2 diabetic patients of South Tamil Nadu

CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide

Contact Info

Product

Resources

About

CYP2C93* gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide